News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Subscribe To Our Newsletter & Stay Updated
